XL184

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Study of XL184 (Cabozantinib) in Adults With Glioblastoma MultiformeNCT00704288ExelixisPhase 2Completed2012-06Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.